Biom'Up S.A. announced unaudited sales results for the first half ended June 30, 2019. For the period, the company reported sales of HEMOBLAST Bellows totaled EUR 1.4 million, a sequential month-over-month growth rate of 23% since global launch in July 2018. HEMOBLAST Bellows sales for first half of 2019 were more than twice as much as the EUR 627,000 recorded for the previous six months. The revenue recorded for HEMOBLAST Bellows during first half of 2019 is also in line with the full-year 2019 guidance for global sales in the range of EUR 4.0 million – EUR 4.5 million. US orders already represent close to 2/3 of total orders, demonstrating HEMOBLAST Bellows' potential in the strategic US market.

The company reiterates its revenue guidance in the range of EUR 4.0 to 4.5 million for 2019 as announced on May 20, 2019. The company remains convinced that HEMOBLAST Bellows has the potential to capture a 15% market share in the US and main European countries in the long term but cannot commit to a precise year in which such level of revenues may be achieved.